SLC6A2 and attention deficit-hyperactivity disorder: Previous research has demonstrated a role for the dopaminergic and noradrenergic systems, as the dopamine and norepinephrine transporters (DAT and NET) are the main targets of methylphenidate [12], which is currently the first-choice medication for ADHD [13].